Patients with moderate to severe atopic dermatitis (also known as eczema) who take a biologic treatment such as dupilumab seem to be protected from developing serious complications of COVID-19 and are also less likely to be hospitalized due to complications. Now, researchers from the Icahn School of Medicine at Mount Sinai have received a grant from the National Institutes of Health (NIH) on behalf of the National Institute of Allergy and Infectious Disease (NIAID) to study the immune responses ...